# **HPV Vaccination as Cancer Prevention: Memphis and Shelby County Updates**

**April 11, 2025** 

Michelle Bowden, MD, FAAP

**Associate Professor of Pediatrics** 

The University of Tennessee Health Science Center

Medical Director, Eating Disorder Program, Le Bonheur Children's Hospital

Past Chair, Memphis and Shelby County HPV Cancer Prevention Roundtable







### **Disclosures**

• Speaker for Merck, Sharp and Dohme



## **Objectives**


- Review prevalence of HPV related cancers and disparities
- Discuss local HPV vaccine uptake as a tool for cancer prevention
- Identify opportunities to improve HPV cancer prevention efforts



Last updated NOVEMBER 2022 PN300538

#### **HPV-Associated Cancer Burden**

- Vagina
- Vulva
- Anus
- Cervix
- Penis
- Oropharynx
- Precancers
- Genital Warts
- Recurrent Respiratory Papillomatosis




www.cdc.gov/HPV



### **HPV-Associated Cancer Disparities by Gender**

• Number of New HPV-Associated Cancers Each Year, by Gender




Centers for Disease Control and Prevention. Cancers Associated with Human Papillomavirus, United States—2017-21.



#### **HPV-Associated Cancer Incidence by Cancer Type**

In the last decade, HPV-associated oropharyngeal cancers diagnoses have surpassed cervical cancer diagnoses.

- 71% of all oropharynx cancers are associated with HPV
  - 85–96% are caused by HPV-16 infections
- 84% of new HPVassociated oropharynx cancer cases are in men






## **High Risk HPV Prevalence Disparities by Race**

Prevalence of high risk HPV types is highest among

- Men
- People who are non-Hispanic and Black.

Figure 4. Prevalence of high-risk genital HPV among adults aged 18–59, by race and Hispanic origin and sex: United States, 2013–2014



<sup>&</sup>lt;sup>1</sup>Percentage for men is significantly higher than women.

NOTES: HPV is human papillomavirus. High-risk genital HPV means tested positive to one or more of the 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68) from a penile or vaginal swab sample. Penile samples were available only for 2013–2014, so all results presented were limited to that cycle. Access data table for Figure 4 at: https://www.cdc.gov/nchs/data/databriefs/db280\_table.pdf#4.

SOURCE: NCHS, National Health and Nutrition Examination Survey, 2013–2014.

<sup>&</sup>lt;sup>2</sup>Percentage is significantly different from non-Hispanic Asian, all, men, and women.

<sup>&</sup>lt;sup>3</sup>Percentage is significantly different from non-Hispanic white, all, men, and women.

<sup>&</sup>lt;sup>4</sup>Percentage is significantly different from non-Hispanic black, all, men, and women.




### **HPV Cancer Prevalence Disparities by Race**

#### Cervical Cancer Incidence and Mortality Rates by Race/Ethnicity, 2018-2022

Age-adjusted Rates per 100,000 People

■ Incidence Rate ■ Mortality Rate




National Cancer Institute, SEER Cancer Stat Facts: Cervix Uteri Cance. Image from kFF.orgr



#### **HPV-Associated Cancers in Tennessee**

#### Rate of New HPV-associated Cancers By State



Area	$\Leftrightarrow$	Age-Adjusted Rate	Case Count
Michigan		12.5	7,717
New Jersey		11.5	6,586
Virginia		11.3	5,778
Washington		11.8	5,246
Arizona		9.9	4,209
Massachuset	ts	11.0	4,809
Tennessee		14.2	5,844
Maryland		11.4	4,222
Missouri		14.5	5,322
Wisconsin		11.8	4,314

Tennessee #10 in the nation


Source - U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; <a href="https://www.cdc.gov/cancer/dataviz">https://www.cdc.gov/cancer/dataviz</a>, released in November 2023.



## HPV Vaccine linked to declining infections and associated cancers

- Initial HPV vaccine released in US in 2006
- Prevents 90% of HPV vaccine type-related cancers, and up to 100% of cervical cancers
- Proven to be safe and effective

Figure 2. Age-Specified Incidences and Trends of Cervical Squamous Cell Carcinoma in Individuals Aged 20 to 24 Years and Human Papillomavirus Virus (HPV) Vaccination Rate (>1 Dose) in Adolescents Aged 13 to 17 Years



- Jiayao Lei, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383:1340-1348
- Liao C, et al. Trends in Human Papillomavirus—Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017. JAMA Netw Open. 2022;5(3):e222530



#### **HPV Vaccination US**

- Advisory Committee on Immunization Practices (ACIP) from CDC recommends vaccination at starting at age
   9<sup>1</sup>
  - Initially for girls, boys added to recommendation in 2011
  - Recommended 2 dose series for those under 15 in 2016
- Healthy People 3030 Goal: 80% vaccination by age 15
  - Would avert 53,300 lifetime cervical cancer cases in the US<sup>2</sup>
  - could lead to the prevention of 934,000 oropharyngeal cancers and could lead to its elimination by late 2070s<sup>3</sup>



<sup>1.</sup> CDC. ACIP Vaccine recommendations.

Dunne, Sex Trans Disease.

<sup>3.</sup> Damgacioglu H, Lancet Regional Health Americas



#### **HPV Vaccination Recommendations**

**ON-TIME** 



AGE: 9-12 years

2 DOSES

Each dose 6-12 months apart

**LATE** 



AGE: 13-14 years

2 DOSES

Each dose 6-12 months apart

LATE: EXTRA DOSE



AGE: 15-26 years

3 DOSES

Second dose 1-2 months after first; Third dose 6 months after first dose **CONSULT** 



AGE: 27-45 years

3 DOSES

Talk with health care provider about HPV vaccination


CDC. HPV Vaccine recommendations.



#### **HPV Vaccination US**

- Healthy People 3030 Goal: 80% vaccination
- In 2022, 58.6% of adolescents aged 13-15 years had received 2 or 3 doses of HPV vaccine
- Annual percentage increase sharply declining.

Percentage of adolescents aged 13-15 years who had received 2 or 3 doses of the human papillomavirus (HPV) vaccine as recommended at time of immunization, 2012-2022




Cancer Trends Progress Report National Cancer Institute, HPV



#### **HPV Vaccination: Where We've Been**

## Rates of HPV Vaccine Initiation Among Adolescents Ages 13-17 in the U.S., by Insurance Status

Share of adolescents who have had at least one HPV vaccine, by insurance status, 2015-2022



The HPV Vaccine Access and Use in the US. kff.org



### Why is HPV Vaccine Uptake Low?




#### **Identifying Barriers:**

- Access to Care
- Incomplete knowledge about availability/importance
- Lack of optimizing opportunities for vaccination
   Patient/Parental Hesitancy
   Vaccine Safety Concerns
   Lack of strong provider recommendation

- Vaccine Misinformation




### **HPV Vaccination: Memphis and Shelby County**





#### **HPV Vaccination: State Data**

# HPV VACCINATION RATES FOR 13-17 YEAR-OLDS AS OF 2023:




Source: Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023.



#### **HPV Vaccination: State Data**


## HPV Vaccination by Race/Ethnicity



Source: Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023.



#### **HPV Vaccination: State Data**



Source: Pingali C, Yankey D, Chen M, et al. National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2023.



#### **HPV Vaccination: Local Data**

#### Shelby County HPV vaccine Data:

• 2019: 26.3%


• 2024: 40.4%

 3.3% higher coverage rate in Shelby County compared to the rest of the state

• 14.1% increase over this

five-year period.


\* According to the Tennessee
Vaccine Information System (TennIIS)



Source: aylor, et al. Local Impact of the Me mphis and She Iby County HPV Cancer Prevention Roundtable on Vaccination Rate. Poster. 2024.



#### **Addressing our Local Barriers: Building Partnerships**





## Working Collectively for Greater impact: HPV Cancer Prevention Roundtable

- Stakeholders initially gathered by gynecologic oncologist Dr. Michael Ulm
- Established in 2021
- Now housed and supported by the St.
   Jude Cancer Prevention Program
- Involves stakeholders across many disciplines: physician, nursing, public health, pharmacy, research, faith leaders, community activists





## **HPV vaccine uptake: Understanding what works**

	Likely Impact
<ul> <li>Intervention targets what people think and feel</li> <li>Messages that increase disease risk appraisals</li> <li>Education campaigns that increase confidence</li> <li>Decision aids</li> <li>Motivational interviewing</li> </ul>	No/very small impact No/very small impact No/very small impact No/very small impact
<ul> <li>Intervention targets social processes</li> <li>Messages that change altruism or free-riding beliefs</li> <li>Descriptive norm messages</li> <li>Social network interventions that build on contagion</li> <li>Healthcare provider recommendations</li> </ul>	No/very small impact Modest impact Modest impact Substantial impact
<ul> <li>Intervention targets direct behavior change</li> <li>Reminder and recalls</li> <li>Presumptive healthcare provider recommendations</li> <li>Onsite vaccinations</li> <li>Default appointments</li> <li>Incentives</li> <li>School and work requirements (mandates)</li> <li>Sanctions</li> </ul>	Modest impact Substantial impact



Brewer NT et al. Increasing Vaccination: Putting Psychological Science Into Action. Psychol Sci Public Interest. 2017 Dec;18(3):149-207. doi: 10.1177/1529100618760521. PMID: 29611455. Brewer NT. What Works to Increase Vaccination Uptake. Academic Pediatrics, Volume 21, Issue 4, S9 - S16.



## **Addressing Barriers: Community Initiatives**



- Hosting "Cancer Survivor School"
- Collaborating with faith communities to provide HPV vaccine education at "Back to School" events and community fairs
- Immunization drives: working with Shelby County Health Department and mobile vaccine clinic
- Providing vaccine communication training
- Providing free resources: videos, postcards, information sheets







## **Addressing Barriers: Legislative Initiatives**

- Friendsgiving collaboration for vaccine advocacy with the TN Families for Vaccines advocacy
- Legislative breakfasts at the state capital that engaged legislators with supportive information about HPV vaccination
- "Day on the Hill" activities



www.tnfamiliesforvaccines.org/



# Addressing Barriers: Clinic/Provider Initiatives



Establishing Learning
Collaboratives with American
Cancer Society

Worked with 7 local clinics in 2022

Celebrating Success:
Development of the HPV
Roundtable Community
Champion award

Promoting Vaccination at Age 9 through educational events and Announcement Approach trainings






Helping providers address hesitancy through motivational interviewing training



## Improving HPV Vaccine Uptake: Clinical Initiatives


- Start HPV vaccination series at age 9
- Standing orders (protocols)
- Provider reminder/recall (advisories)
- Patient reminder/recall
- Health care system + community based interventions
- Expand access points (ie mobile units)
- Build (or rebuild) confidence in HPV vaccination



Resources available through the ACS National HPV Vaccination Roundtable



## The Biggest Predictor of HPV Vaccine Uptake: A Provider recommendation



Announcement Approach by Dr. Noel Brewer, Dr. Melissa Gilkey, et al., see HPViq.org for more information



## Improving HPV Vaccination: Communicating the need

- In both pediatric and adult studies, patients who are provided a strong provider recommendation are significantly more likely to become vaccinated
- Consider scripting a message for vaccinators:

"I STRONGLY recommend your child receive the HPV vaccine TODAY. I recommend it to all my patients 9 or older. Human papilloma virus is a VERY common virus to which 80% of us are exposed during our lifetime and can cause cancer. Giving this vaccine to your child now can prevent cancer in his/her future, and we know that the vaccine is EFFECTIVE with an excellent safety profile."




## **Building Confidence for HPV-related Concerns**

Equip Providers with basic messages for common concerns

- Risk: Highly Prevalent Disease state
- Importance: For both genders
- Benefit: Lasting immunity for Cancer Prevention
- Concerns: Excellent Safety Profile

**Empathize: Personal Connection Matters** 

Learning to listen without reinforcing misinformation



Piltch-Loeb R, DiClemente R. Vaccines (Basel). 2020.



### Improving Local HPV Vaccination: Find your "Why"

FIND YOUR

WHY

AND YOU'LL FIND YOUR



- JOHN C. MAXWELL





## **HPV Cancer prevention is possible. HPV Vaccination is Cancer Prevention.**





## Thank you!

For more information about the Memphis and Shelby County HPV Vaccination Roundtable, scan below!

Visit our webpage by scanning the QR Code



Michelle Bowden mbowden@uthsc.ed

U

Join the Memphis Roundtable by scanning the QR Code





#### Thank you!

- Lechner, M., Liu, J., Masterson, L. *et al.* HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. *Nat Rev Clin Oncol* **19**, 306–327 (2022). <a href="https://doi-org.ezproxy.uthsc.edu/10.1038/s41571-022-00603-7">https://doi-org.ezproxy.uthsc.edu/10.1038/s41571-022-00603-7</a>
- Centers for Disease Control and Prevention. Cancers Associated with Human Papillomavirus. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2024.
- American Cancer Society. Cervical Cancer Disparities Fact Sheet. 2024.
   https://www.fightcancer.org/sites/default/files/just\_the\_facts\_cervical\_cancer\_disparities\_fact\_sheet\_final\_2.21.24.pdf
- Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States. Sex Transm Dis. 2014 Nov;41(11):656-9. doi: 10.1097/OLQ.000000000000199. PMID: 25299411; PMCID: PMC6745684.
- Patel, P., Sun, L., & Zhan, Y. (2022). Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. *The Lancet Regional Health Americas, 8,* 100143. <a href="https://doi.org/10.1016/j.lana.2021.100143">https://doi.org/10.1016/j.lana.2021.100143</a>
- Cancer Trends Progress Report
   National Cancer Institute, NIH, DHHS, Bethesda, MD, March 2024, <a href="https://progressreport.cancer.gov">https://progressreport.cancer.gov</a>.
- The HPV Vaccine Access and Use in the US. https://www.kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-access-and-use-in-the-u-s/
- St. Jude Cancer Prevention website. https://www.stjude.org/research/comprehensive-cancer-center/hpv-cancer-prevention-program/hpv-cancer-prevention-roundtable-memphis-shelby.html
- Taylor, A; Mitchell, K. Brown, J., Stubbs, A.,. Brandt, H. Local Impact of the Me mphis and She Iby County HPV Cancer Prevention Roundtable on Vaccination Rate. shttps://sjr-redesign.stjude.org/content/dam/research-redesign/centers-initiatives/hpv-cancer-prevention-program/hpv-resources/nic-2024-memphis-roundtable.pdf
- Jin SW, Lattimore DC, Harlin E, Davis L, Erholtz V, Brandt HM. Medical and public health professionals' perceived facilitators and barriers of human papillomavirus (HPV) vaccination among African American adolescents in Shelby County, Tennessee. BMC Health Serv Res. 2023 May 10;23(1):469.
- Piltch-Loeb R, DiClemente R. The Vaccine Uptake Continuum: Applying Social Science Theory to Shift Vaccine Hesitancy. Vaccines (Basel). 2020 Feb 7;8(1):76. doi: 10.3390/vaccines8010076. PMID: 32046228; PMCID: PMC7157682.